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ABSTRACT
 
Objective:
 
Using a conceptual model of collaborative
working relationships between pharmacists and physi-
cians, a measure for physician–pharmacist collaboration
from the physician perspective was developed. The meas-
ure was analyzed for its factor structure, internal consist-
ency, construct validity, and other psychometric
properties.
Methods: An initial 27-item Physician–Pharmacist Col-
laboration Instrument (PPCI) was developed to assess
seven themes about professional relationships using Lik-
ert scales. The PPCI was mailed to a random sample of
1000 primary care physicians. Principal component anal-
ysis was used to assess the structure and uncover under-
lying dimensions of the initial instrument. Items were
evaluated for inclusion or exclusion into a reﬁned instru-
ment. Internal consistency was assessed by calculating
Alpha coefﬁcients for each identiﬁed factor. Convergent
validity was assessed using Spearman correlations
between the identiﬁed factors and a previous measure of
collaborative care. After measure reﬁnement, conﬁrma-
tory factor analysis was used to evaluate the ﬁt of both
versions of the instrument.
Results: Three hundred forty usable surveys were
returned for a response rate of 34%. Almost 70% of the
respondents were male with a mean age of 45.8. A major-
ity were family practice physicians (72.1%) in private
practice (67.3%). Three unique factors were identiﬁed
during principal component analysis and utilized in a
conﬁrmatory factor analysis. Both a full and a 14-item
reduced model were constructed and tested. Cronbach’s
alpha for the three factors of the full model ranged from
0.91 to 0.97, while the reliability for the reduced model
ranged from 0.86 to 0.96. Comparative ﬁt indexes of 0.97
and 0.98 were obtained, indicating good ﬁt for the
models.
Conclusions: The results indicate good reliability and
validity of the reﬁned (14-item) PPCI. This instrument can
be useful as a research tool for assessment of the physi-
cians’ perspective about a physician–pharmacist relation-
ship. Further research is warranted to examine if the
extent of relationship development, as measured with the
PPCI, can affect patient care outcomes.
Keywords: collaboration, communication, coordinated
care, physician–pharmacist relationship.
 
Introduction
 
Collaboration among health care professionals has
been deﬁned as a “joint communicating and deci-
sion-making process with the goal of satisfying the
patient’s wellness and illness needs while respecting
the unique qualities and abilities of each profes-
sional” [1]. This deﬁnition can be reﬂected in rela-
tionships between physicians and pharmacists.
Numerous studies have concluded that coordinated
care between physicians and pharmacists can
improve patient care outcomes [2–9]. Likewise,
reports of pharmacists’ activities indicate that col-
laborative practice with physicians is occurring fre-
quently [5,10–14]. In fact, recent position articles
by the American College of Physicians—American
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Society of Internal Medicine and the American Col-
lege of Clinical Pharmacy support physician–phar-
macist collaboration for managing medication [15].
Nevertheless, the degree of collaboration that
occurs between an individual physician and phar-
macist can vary greatly. For patients to beneﬁt from
physician–pharmacist collaboration, its effect on
patient care outcomes needs to be understood. As a
research tool, a valid measure of collaborative care
may help explain different levels of success among
collaborative health-care service interventions. It
is possible that patient health-care outcomes are
related to the degree of collaboration between
health-care providers. To date, there has been no
measure to assess the degree of collaboration
between a physician and pharmacist. Recently, a
theoretical framework of physician–pharmacist col-
laborative relationships has been developed [16].
Based on this theoretical framework, the objective
of the present study was to develop, reﬁne, and test
the reliability and validity of a measurement tool for
physician–pharmacist collaboration.
In the theoretical framework, collaborative rela-
tionships are developed through ﬁve progressive
stages: Stage 0—Professional Awareness; Stage 1—
Professional Recognition; Stage 2—Exploration
and Trial; Stage 3—Professional Relationship
Expansion; and Stage 4—Commitment to the Col-
laborative Working Relationship. Contributions of
both physician and pharmacist allow the relation-
ship to grow, with higher stages representing an
expanded relationship. Certain variables, such as
the nature and scope of social exchange drive the
development of a collaborative relationship.
Interactions among physicians and pharmacists
are viewed as exchanges. At Stage 0, exchange is
minimal while Stage 1 exchange is mostly unilateral
or driven by one party. As the relationship
progresses, the exchanges become bilateral in which
both parties are active. Stage 4 represents a com-
mitted and sustained relationship characterized by
bilateral communication and mutual trust. In this
model, delivery of health-care services by a pharma-
cist expands as the stage of collaboration increases.
Consequently, pharmacists may need to operate in
higher stages of this model to deliver health care
services that affect patient outcomes.
The theoretical framework formed a basis to
construct a 27-item questionnaire to measure phy-
sicians’ views of physician–pharmacist collabora-
tive relationships. The items on the questionnaire
were designed to assess the nature and scope of
social exchange that drive the relationship. Before
employing this questionnaire to evaluate effects on
patient care outcomes, the purpose of the current
study was to subject the instrument to rigorous val-
idation testing.
 
Methods
 
Items on the Physician–Pharmacist Collaboration
Instrument (PPCI) were developed to capture the
nature and scope of social exchange which drive a
professional relationship. These items were crafted
based on seven themes surrounding a professional
relationship: collaborative care, commitment,
dependence symmetry, bidirectional communica-
tion, trust, initiating behavior, and conﬂict
resolution.
Item measures were developed using literature
from interpersonal, business, and health-care rela-
tionships [17–34].
Six of the seven concepts were measured using a
seven-point Likert scale with respondents indicating
1 (very strongly disagree) to 7 (very strongly agree)
for each item. The intermediate points on the scale
were also deﬁned from strongly disagree to strongly
agree. Respondents were asked to consider their
relationship with the pharmacist whom they work
most often. They were told to respond to each item
based on the interactions with this pharmacist over
time. The other concept, initiating behavior, was
measured on a ﬁve-point scale (1 
 
=
 
 not at all, 5 
 
=
 
 to
a great extent). The respondent was asked to indi-
cate the extent to which the pharmacist had per-
formed each of ﬁve activities.
An initial draft of the concept deﬁnitions and
items was distributed to ﬁve physicians who were
known to have interaction with pharmacists. These
physicians were asked to provide comments related
to the face validity of the instrument. Subsequent
revisions to the items followed the feedback on face
validity provided by these physicians.
A pilot test of the 27-item questionnaire was con-
ducted. One hundred and ten physicians afﬁliated
with the University were asked to complete the
questionnaire. In addition, the physicians were
asked to complete a separate nine-item instrument
as an initial test of construct validity. This second
instrument (i.e., Baggs) had been originally designed
and validated to measure collaboration and satis-
faction about care between physicians and nurses
[17]. The Baggs measures were modiﬁed slightly to
reﬂect a pharmacist perspective rather than a nurse.
Sixty-eight surveys (61.8%) were returned. Results
from the pilot testing indicated that the items had
good internal consistency [35]. Also, the seven con-
cepts were signiﬁcantly, positively correlated among
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each other and between the collaboration scale
from Baggs. Therefore, further evaluation focused
on identifying latent factors that conceptually com-
prise physician–pharmacist collaboration.
Using data from the pilot test, minor changes
were made to the PPCI. Then, using traditional sur-
vey techniques, the 27-item PPCI and the modiﬁed
Baggs’ instrument were mailed to a random sample
of 1000 primary care physicians in the state of
Iowa. The list of physicians was generated from a
database of more than 5000 registered physicians in
Iowa maintained by the University of Iowa, Ofﬁce
of Statewide Clinical Education Program. Primary
care physicians constituted family medicine, general
internal medicine, and pediatrics.
A cover letter described the purpose and proce-
dures of the survey and requested physicians to
return the survey in the provided self-addressed,
stamped envelop. Each survey was marked with an
identiﬁcation number. The purpose of the ID
number was to coordinate follow-up mailings. Phy-
sicians could remove the ID number and return the
survey anonymously. Respondents were asked to
return the survey blank if they did not wish to par-
ticipate and receive follow-up mailings. A reminder
postcard was sent to all nonrespondents after seven
days. A ﬁnal follow-up survey was mailed to non-
respondents 10 days after the postcard. The study
was approved by the University of Iowa Human
Subjects Institutional Review Board.
First, principal component analysis was applied
to the 27-items. Examination of the eigenvalues and
scree plotting of the values determined the number
of latent factors in the PPCI [36,37]. Then, factor
analysis with promax rotation was used to provide
information regarding how each item contributed
to the measurement of a construct. Using this infor-
mation, individual items were evaluated for inclu-
sion or exclusion based on the factor loading
generated by the ﬁnal solution of the factor analysis,
simple structure, and the logical interpretability of
the item in relation to the extracted factor. In addi-
tion, items were further examined for inclusion into
a shortened version of the instrument. Decisions to
remove items were based on item to total correla-
tions and maintaining theoretically meaningful con-
structs while eliminating potentially redundant
questions. Therefore, both an initial and reﬁned/
shortened model describing the resulting item struc-
ture of the PPCI was constructed.
Reliability and validity of the PPCI was evaluated
using several methods. Internal consistency reliabil-
ity was evaluated using the Cronbach 
 
a
 
 coefﬁcient
[38]. Construct validity was examined with corre-
lations between the factors of the PPCI and the pre-
viously validated collaboration and satisfaction
scales developed by Baggs [17]. We hypothesized
that the PPCI would be positively correlated with
both the collaboration scale and the satisfaction
scale from the Baggs’ instrument [39,40]. Structural
equation modeling provided an objective test of the
initial and reﬁned models using both the compara-
tive ﬁt index (CFI) and the root mean square error
of approximation (RMSEA) [41–43]. All data and
factor analytic techniques were conducted using
SAS
 
®
 
 and AMOS
 
®
 
 software.
 
Results
 
A total of 394 (39.4%) surveys were returned.
There were 340 usable surveys for a response rate of
34%. The most common reasons for an unusable
survey were: the physician was no longer in practice
(n 
 
=
 
 6), the physician declined participation
(n 
 
=
 
 20), or inability of the physician to identify a
single pharmacist whom they worked with regularly
(n 
 
=
 
 23).
The characteristics of the survey respondents are
presented in Table 1. The majority of respondents
were male (69.7%), family medicine physicians
(72.1%) working in a private practice setting
(67.3%). This sample is similar to the population of
primary care physicians in Iowa: 71.2% male,
67.7% family medicine, and 80.2% in private prac-
tice [44]. Slightly less than half of the respondents
(43.3%) had some type of academic afﬁliation
while more than 90% were board certiﬁed.
The principal component analysis indicated three
factors with eigenvalues greater than one. These
 
Table 1
 
Characteristics of  survey respondents (n 
 
=
 
 340)
 
Variable Result
Age (year)* 45.8 
 
± 
 
9.9
Male (%) 69.7
Practice type (%)
Family medicine 72.1
Internal medicine 16.0
Pediatrics 11.9
Practice setting (%)
Private practice 67.3
Academic Institution 13.8
Health maintenance organization 3.0
Other publicly funded institution 4.8
Other 11.1
Years in practice* 16.0 ± 10.9
Years of  residency training* 2.8 ± 0.9
Academic afﬁliation (%)
Full-time faculty 21.0
Part-time/adjunct faculty 22.3
No afﬁliation 56.7
Board certiﬁcation (%) 91.3
 
*Data are mean ± SD.
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three factors explained 76% of the variance. Scree
plot analyses supported a three-factor solution. A
three-factor oblique solution was obtained for entry
into a conﬁrmatory factor analysis. In general, Fac-
tor 1, termed Trustworthiness, is composed of items
from trust, commitment, and bidirectional commu-
nication. Factor 2 comprises items from conﬂict res-
olution and dependence symmetry and is named
Role Speciﬁcation. Factor 3, termed Relationship
Initiation, contained only items from the initiating
behavior domain. One of the original 27 items did
not achieve a single factor loading greater than 0.5
in the exploratory factor analysis. This item was not
included in the conﬁrmatory factor analyses.
Conﬁrmatory factor analysis was performed on
both the initial (full) model and a reduced model
using the three factors. The 14-item reduced model
was constructed in which items were removed based
on item to total correlations and maintaining theo-
retically meaningful constructs while eliminating
potentially redundant questions (Appendix 1). The
reduced PPCI was developed to provide a more
streamlined and less time-consuming instrument.
The level of correlation between the factors, indi-
cated by the double-headed arrows and coefﬁcients,
ranges from 0.52 to 0.81 for the full model and 0.52
to 0.79 in the reduced model (Fig. 1). The CFI for
the initial model is 0.97 and 0.98 for the reﬁned
model. Both indices exceed the 0.95 criteria level
used to indicate a close ﬁt [45]. Also, the RMSEA is
0.09 for the initial and reﬁned models. According to
Browne and Cudek, an RMSEA of less than 0.05
indicates a close ﬁt, and a value of 0.08 to 0.1 indi-
cates a moderate ﬁt of the models [42].
Internal consistency for the three factors in the
initial PPCI ranged from 0.91 to 0.97 (Table 2). The
alpha coefﬁcients for the three factors in the reﬁned
PPCI ranged from 0.86 to 0.96. Each of the three
factors was positively and signiﬁcantly correlated
with the collaborative care scale and the satisfaction
scale developed by Baggs, indicating appropriate
nomological and construct validity (Table 3) [17].
The correlation coefﬁcients from our domains are
expected to be higher with the Baggs collaboration
scale because they measure very similar constructs.
Likewise, the correlation coefﬁcients with the Baggs
 
Figure 1
 
Conﬁrmatory factor analysis of  reﬁned PPCI. *See
Appendix 1 for items listed by number.
1 
2 
3 
4 
6 
5 
8 
9 
10 
11 
13 
12 
14 
7 
*PPCI  Item
CFI = 0.98     RMSEA = 0.09
0.90
Trustworthiness 
Role Specification 
Relationship 
Initiation
0.89
0.94
0.91
0.91
0.87
0.84
0.89
0.83
0.78
0.83
0.85
0.77
0.86
0.62
0.79
0.52
 
Table 2
 
Descriptive statistics and reliabilities for the initial
and reﬁned Physician–Pharmacist Collaboration Instrument
(PPCI)
 
Latent factor
Scale
mean 
 
± 
 
SD
Item
mean
Coefﬁcient 
 
a
 
Initial PPCI
Trustworthiness
(10 items)
58.1 
 
± 
 
11.4 5.8 0.97
Role speciﬁcation
(11 items)
53.9 
 
± 
 
13.5 4.9 0.96
Relationship initiation
(5 items)
18.0 
 
± 
 
4.7 3.6 0.91
Reﬁned PPCI
Trustworthiness
(6 items)
35.0 
 
± 
 
6.8 5.8 0.96
Role speciﬁcation
(5 items)
24.6 
 
± 
 
6.3 4.9 0.91
Relationship initiation
(3 items)
10.9 
 
± 
 
2.8 3.5 0.86
 
Table 3
 
Spearman’s correlation coefﬁcients between latent
factors of  PPCI and Baggs collaboration and satisfaction scale*
 
PPCI latent factor
Baggs
collaboration scale
Baggs
satisfaction scale
Initial PPCI
Trustworthiness
(10 items)
0.68 0.40
Role speciﬁcation
(11 items)
0.84 0.25
Initiating behavior
(5 items)
0.61 0.33
Reﬁned PPCI
Trustworthiness
(6 items)
0.64 0.40
Role speciﬁcation
(5 items)
0.77 0.25
Initiating behavior
(3 items)
0.62 0.32
 
*All correlations are signiﬁcant at P < 0.01.
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satisfaction scale should be positively correlated but
to a less degree than the collaboration scale because
satisfaction is a related construct. Previous research
has shown that collaboration and satisfaction are
correlated [39,40].
 
Discussion
 
The results support validity arguments related to
the interpretation of both the initial and the reﬁned
PPCI. Based on principal component analysis, we
hypothesized that there are three factors describing
the model. Then, conﬁrmatory factor analysis
examined the factor structure to develop a reﬁned
and conceptually meaningful description of the fac-
tors. The validity of a 14-item reﬁned model was
supported using a conﬁrmatory factor analysis. As a
test of convergent validity, we examined the corre-
lations between the PPCI and scales of collabora-
tion and satisfaction previously validated with data
from physician-nurse relations [17]. Both the initial
and reﬁned PPCI were signiﬁcantly positively corre-
lated with Baggs’s scales. The 14-item reﬁned PPCI
is preferred over the 26-item measure because it
is shorter yet possesses similar psychometric
properties.
The reﬁned PPCI contains three meaningful fac-
tors. One factor focuses on relationship initiation
behaviors. This behavior refers to the actions of one
party to determine the needs of another party;
thereby facilitating relationship development. For
example, suppose that a pharmacist is consistently
answering questions about anticoagulation from a
particular physician. To initiate a collaborative rela-
tionship, the pharmacist asks to meet with the phy-
sician to discuss mutual interest in a pharmacist-run
anticoagulation service.
The second factor is a composite of items from
trust, commitment, and communication. We label
this factor trustworthiness. Conceptually, this factor
encompasses a physician’s ability to trust a pharma-
cist’s word and expertise. That is, a high rating on
this dimension means that if a pharmacist says he/
she will be able to perform a particular task or role,
then the physician will trust that the job will be
done as expected. Also in the trustworthiness factor
are single items on commitment and two-way com-
munication. Previous research has reported a posi-
tive association between trust and commitment
[34,46] as well as trust and two-way communica-
tion [47]. Trust, or conﬁdence in another’s abilities,
can result in greater dialogue about problems
encountered during patient care. Similarly, once a
physician has developed trust in a pharmacist, he or
she is more likely to be committed to interact with
that pharmacist in the future [34].
The third factor is a mix of items representing
dependence of practitioners on each other and
negotiating acceptable activities for the practition-
ers. We labeled this factor role speciﬁcation. This
factor addresses the interactions between pharma-
cists and physicians in which they reach agreement
on roles and responsibilities for each other in caring
for mutual patients. The more equitably the roles
are assigned, the more balanced will be the depend-
ence of the practitioners on each other.
As a validated measure of the physicians’ view of
their collaboration with a pharmacist, the PPCI can
be used in various situations. As a research tool, the
instrument can measure the “strength” of collabo-
ration. A growing literature documents the effects
of physician–pharmacist collaboration on manag-
ing drug therapy [2–9]. Study results vary widely in
the absolute beneﬁt derived from such collaborative
efforts. An important component underlying suc-
cessful cooperative drug therapy management is the
relationship between the physician and the pharma-
cist. It is possible that the variability reported in the
outcomes generated by collaborative care is directly
related to the “strength” of the collaborative rela-
tionship between the physician and pharmacist.
Some successful interventions may have operated in
higher stages of collaboration while unsuccessful
interventions may have operated in lower stages.
Naturally, one could hypothesize that a strong phy-
sician–pharmacist collaborative relationship would
be a positive inﬂuence on patient care outcomes.
The PPCI can be used in research studies to test this
hypothesis and to evaluate methods/interventions
for improving these relationships.
Similarly, the PPCI could be used as a practice
assessment tool. Practitioners can use the PPCI as a
measure of their collaborative relationship with a
particular colleague. Over time, as the relationship
develops, the score on the PPCI should increase,
indicating advancement in the collaborative rela-
tionship and a higher stage in the theoretical model
proposed by McDonough and Doucette [16]. Phar-
macists who are looking to establish a collaborative
relationship may use the PPCI as an initial gauge of
physician’s view of their relationship. The PPCI
could be provided to the physician again at a later
time to see if the collaborative relationship has
grown.
The PPCI may also be used by administrators
as part of performance assessment. For instance,
there may be an expectation for a pharmacist to
develop a medication management service in a
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particular setting. As part of that pharmacist’s per-
formance, the PPCI could measure the physician’s
view of the collaborative relationships developed
between the pharmacist and the physicians. Also,
when looking to implement medication manage-
ment services, administrators could use the PPCI
to identify which physician(s) are likely to best
form a collaborative relationship with a given
pharmacist.
 
Limitations and Future Research
 
Although the reliability and validity of the PPCI
are favorable, there are some limitations. The
response rate of the survey was modest at 34%.
Nevertheless, the 340 respondents provided an
adequate sample for purposes of validation testing.
Also, the wording of the PPCI may encourage
some response bias. The instrument asks respond-
ents to consider their answers based on “a pharma-
cist with whom you work the most.” Physician
respondents who do not have a particular pharma-
cist as a reference may not complete the PPCI.
Therefore, the results may reﬂect physicians who
more often work with a pharmacist. Similarly,
there was no method to ascertain which pharma-
cist served as the reference point. Possibly, one
pharmacist may have been the reference point
for several physicians and could inﬂuence the
responses. It is also possible that a physician may
work equally among pharmacists from a particular
pharmacy. As such, the pharmacy may have been
the reference rather than one particular pharma-
cist. Perhaps in future use of the PPCI, the speciﬁc
pharmacist could be indicated on the instrument
for the physician’s reference.
In addition, this validation testing was con-
ducted on the measure from the physician’s perspec-
tive. Future work is ongoing to also examine input
from pharmacists to assess their perceptions of a
collaborative relationship with a given physician
[48,49]. Future research is also needed to elucidate
interpretation of the PPCI scores. For example,
what score would translate into a meaningful
change in a professional relationship? Also, is there
a range of scores that are associated with a given
relationship stage from the theoretical model? At
this time, it is not clear what score from the PPCI
translates into a particular relationship stage.
Finally, the current validation study was conducted
using ambulatory/primary care physicians. Validity
testing of this instrument for hospital-based or spe-
cialty physicians may be different and requires fur-
ther research.
 
Conclusions
 
The results support the validity of the PPCI as a
measure of collaboration between physician and
pharmacist. In the factor analyses, three latent fac-
tors emerged as domains of physician–pharmacist
collaboration: trustworthiness, role speciﬁcation,
and initiating behavior. The PPCI may be useful as
a research measure, a clinical assessment tool, or
as a performance assessment instrument. Further
research is warranted to continue validation of this
instrument.
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Appendix 1 Reduced Physician–Pharmacist 
Collaboration Instrument (PPCI) Items
 
Trustworthiness*
 
1) The pharmacist is credible.
2) I trust this pharmacist’s drug expertise.
3) I can count on this pharmacist to do what he/
she says.
4) Communication between this pharmacist and
myself is two-way.
5) I intend to keep working together with this
pharmacist.
6) My interactions with this pharmacist are char-
acterized by open communication of both
parties.
 
Role Speciﬁcation*
 
7) This pharmacist and I negotiate to come to
agreement on our activities in managing drug
therapy.
8) This pharmacist and I are mutually dependent
on each other in caring for patients.
9) I will work with this pharmacist to overcome
disagreements on his/her role in managing
drug therapy.
10) In providing patient care, I need this pharma-
cist as much as this pharmacist needs me.
11) This pharmacist depends on me as much as I
depend on him/her.
 
Relationship Initiation
 
†
 
12) Spent time trying to learn how he/she can help
you provide better care.
13) Showed an interest in helping you improve
your practice.
14) Provided information to you about a speciﬁc
patient.
 
*Measured on a seven-point Likert scale from 1—Very
Strongly Disagree to 7—Very Strongly Agree.
 
†
 
Measure on a ﬁve-point scale for 1—Not at all to 5—To a
great extent. The stem is phrased as “Please indicate the
extent to which this pharmacist has.”
